This work is licensed under the Creative Commons Attribution 4.0 International License.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29. doi: 10.3322/caac.21254SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin20156552910.3322/caac.21254Open DOISearch in Google Scholar
Xu Y, Hu Y, Xu T, Yan K, Zhang T, Li Q, et al. RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. Cell Rep 2021; 37: 109854. doi: 10.1016/j.celrep.2021.109854XuYHuYXuTYanKZhangTLiQRNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damageCell Rep20213710985410.1016/j.celrep.2021.109854Open DOISearch in Google Scholar
Kumar V, Yadavilli S, Kannan R. A review on RNAi therapy for NSCLC: opportunities and challenges. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021; 13: e1677. doi: 10.1002/wnan.1677KumarVYadavilliSKannanRA review on RNAi therapy for NSCLC: opportunities and challengesWiley Interdiscip Rev Nanomed Nanobiotechnol202113e167710.1002/wnan.1677Open DOISearch in Google Scholar
Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, Brzezianska-Lasota E. Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J Mol Sci 2021; 22: 8856. doi: 10.3390/ijms22168885KryczkaJKryczkaJCzarnecka-ChrebelskaKHBrzezianska-LasotaEMolecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapyInt J Mol Sci202122885610.3390/ijms22168885Open DOISearch in Google Scholar
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021; 27: 1345–56. doi: 10.1038/s41591-021-01450-2WangMHerbstRSBoshoffCToward personalized treatment approaches for non-small-cell lung cancerNat Med20212713455610.1038/s41591-021-01450-2Open DOISearch in Google Scholar
Saha SK, Islam SMR, Kwak KS, Rahman MS, Cho SG. PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis. Cancer Gene Ther 2020; 27: 147–67. doi: 10.1038/s41417-019-0109-7SahaSKIslamSMRKwakKSRahmanMSChoSGPROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysisCancer Gene Ther2020271476710.1038/s41417-019-0109-7Open DOISearch in Google Scholar
Luo W, Wang J, Xu W, Ma C, Wan F, Huang Y, et al. LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. Cell Death Dis 2021; 12: 1043. doi: 10.1038/s41419-021-04296-1LuoWWangJXuWMaCWanFHuangYLncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancerCell Death Dis202112104310.1038/s41419-021-04296-1Open DOISearch in Google Scholar
Brown CW, Amante JJ, Chhoy P, Elaimy AL, Liu H, Zhu LJ, et al. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev Cell 2019; 51: 575–86.e574. doi: 10.1016/j.devcel.2019.10.007BrownCWAmanteJJChhoyPElaimyALLiuHZhuLJProminin2 drives ferroptosis resistance by stimulating iron exportDev Cell20195157586.e57410.1016/j.devcel.2019.10.007Open DOISearch in Google Scholar
Brown CW, Chhoy P, Mukhopadhyay D, Karner ER, Mercurio AM. Targeting prominin2 transcription to overcome ferroptosis resistance in cancer. EMBO Mol Med 2021; 13: e13792. doi: 10.15252/emmm.202013792BrownCWChhoyPMukhopadhyayDKarnerERMercurioAMTargeting prominin2 transcription to overcome ferroptosis resistance in cancerEMBO Mol Med202113e1379210.15252/emmm.202013792Open DOISearch in Google Scholar
Li W, Zhu Y, Zhang K, Yu X, Lin H, Wu W, et al. PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer. Exp Mol Med 2020; 52: 409–22. doi: 10.1038/s12276-020-0390-4LiWZhuYZhangKYuXLinHWuWPROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancerExp Mol Med2020524092210.1038/s12276-020-0390-4Open DOISearch in Google Scholar
Song SH, Kim TY. CTCF, cohesin, and chromatin in human cancer. Genomics Inform 2017; 15: 114–122. doi: 10.5808/GI.2017.15.4.114SongSHKimTYCTCF, cohesin, and chromatin in human cancerGenomics Inform20171511412210.5808/GI.2017.15.4.114Open DOISearch in Google Scholar
Guo Y, Perez AA, Hazelett DJ, Coetzee GA, Rhie SK, Farnham PJ. CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops. Genome Biol 2018; 19: 160. doi: 10.1186/s13059-018-1531-0GuoYPerezAAHazelettDJCoetzeeGARhieSKFarnhamPJCRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loopsGenome Biol20181916010.1186/s13059-018-1531-0Open DOISearch in Google Scholar
Zhang B, Zhang Y, Zou X, Chan AW, Zhang R, Lee TK, et al. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. J Pathol 2017; 243: 418–30. doi: 10.1002/path.4976ZhangBZhangYZouXChanAWZhangRLeeTKThe CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinomaJ Pathol20172434183010.1002/path.4976Open DOISearch in Google Scholar
Lai Q, Li Q, He C, Fang Y, Lin S, Cai J, et al. CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. Aging 2020; 12: 16270–93. doi: 10.18632/aging.103648LaiQLiQHeCFangYLinSCaiJCTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axisAging202012162709310.18632/aging.103648Open DOISearch in Google Scholar
Sun Q, Zhang SY, Zhao JF, Han XG, Wang HB, Sun ML. HIF-1alpha or HOTTIP/CTCF promotes head and neck squamous cell carcinoma Progression and drug resistance by targeting HOXA9. Mol Ther Nucleic Acids 2020; 20: 164–75. doi: 10.1016/j.omtn.2019.12.045SunQZhangSYZhaoJFHanXGWangHBSunMLHIF-1alpha or HOTTIP/CTCF promotes head and neck squamous cell carcinoma Progression and drug resistance by targeting HOXA9Mol Ther Nucleic Acids2020201647510.1016/j.omtn.2019.12.045Open DOISearch in Google Scholar
Li H, Lin PH, Gupta P, Li X, Zhao SL, Zhou X, et al. MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. Mol Cancer 2021; 20: 118. doi: 10.1186/s12943-021-01418-3LiHLinPHGuptaPLiXZhaoSLZhouXMG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancerMol Cancer20212011810.1186/s12943-021-01418-3Open DOISearch in Google Scholar
Wang S, Wang L, Hu H, Dong P. MiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9. Allergol Immunopathol 2021; 49: 80–8. doi: 10.15586/aei.v49i6.451WangSWangLHuHDongPMiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9Allergol Immunopathol20214980810.15586/aei.v49i6.451Open DOISearch in Google Scholar
He Y, Li Q, Zhou W, Gu Y, Jiang Y. Coniferyl aldehyde alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via JAK2-STAT1 pathway in acute pneumonia. Allergol Immunopathol 2021; 49: 72–7. doi: 10.15586/aei.v49i5.464HeYLiQZhouWGuYJiangYConiferyl aldehyde alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via JAK2-STAT1 pathway in acute pneumoniaAllergol Immunopathol20214972710.15586/aei.v49i5.464Open DOISearch in Google Scholar
Yang Y, Yang X, Wu Y, Fu M. METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2. Allergol Immunopathol 2021; 49: 49–56. doi: 10.15586/aei.v49i5.445YangYYangXWuYFuMMETTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2Allergol Immunopathol202149495610.15586/aei.v49i5.445Open DOISearch in Google Scholar
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalAGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin20186839442410.3322/caac.21492Open DOISearch in Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30. doi: 10.3322/caac.21387SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin20176773010.3322/caac.21387Open DOISearch in Google Scholar
Nguyen TT, Gapihan G, Tetu P, Pamoukdjian F, El Bouchtaoui M, Leboeuf C, et al. Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes. Clin Transl Med 2020; 10: e198. doi: 10.1002/ctm2.198NguyenTTGapihanGTetuPPamoukdjianFEl BouchtaouiMLeboeufCIncreased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodesClin Transl Med202010e19810.1002/ctm2.198Open DOISearch in Google Scholar
Liu W, Wang H, Bai F, Ding L, Huang Y, Lu C, et al. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-kappaB. Cell Prolif 2020; 53: e12776. doi: 10.1111/cpr.12776LiuWWangHBaiFDingLHuangYLuCIL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-kappaBCell Prolif202053e1277610.1111/cpr.12776Open DOISearch in Google Scholar
Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol 2022; 40: 546–555. doi: 10.1200/JCO.21.01589ChaftJEShyrYSepesiBFordePMPreoperative and postoperative systemic therapy for operable non-small-cell lung cancerJ Clin Oncol20224054655510.1200/JCO.21.01589Open DOISearch in Google Scholar
Taheri M, Shoorei H, Tondro Anamag F, Ghafouri-Fard S, Dinger ME. LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin. Exp Mol Pathol 2021; 123: 104602. doi: 10.1016/j.yexmp.2021.104602TaheriMShooreiHTondro AnamagFGhafouri-FardSDingerMELncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatinExp Mol Pathol202112310460210.1016/j.yexmp.2021.104602Open DOISearch in Google Scholar
Chen TY, Zhou J, Li PC, Tang CH, Xu K, Li T, et al. SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling. Med Oncol 2022; 39: 36. doi: 10.1007/s12032-021-01626-3ChenTYZhouJLiPCTangCHXuKLiTSOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signalingMed Oncol2022393610.1007/s12032-021-01626-3Open DOISearch in Google Scholar
Wang W, Zhao M, Cui L, Ren Y, Zhang J, Chen J, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer 2020; 19: 134. doi: 10.1186/s12943-020-01256-9WangWZhaoMCuiLRenYZhangJChenJCharacterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancerMol Cancer20201913410.1186/s12943-020-01256-9Open DOISearch in Google Scholar
Fang C, Wang Z, Han C, Safgren SL, Helmin KA, Adelman ER, et al. Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biol 2020; 21: 247. doi: 10.1186/s13059-020-02152-7FangCWangZHanCSafgrenSLHelminKAAdelmanERCancer-specific CTCF binding facilitates oncogenic transcriptional dysregulationGenome Biol20202124710.1186/s13059-020-02152-7Open DOISearch in Google Scholar
Wang L, Peng Q, Yin N, Xie Y, Xu J, Chen A, et al. Chromatin accessibility regulates chemotherapy-induced dormancy and reactivation. Mol Ther Nucleic Acids 2021; 26: 269–279. doi: 10.1016/j.omtn.2021.07.019WangLPengQYinNXieYXuJChenAChromatin accessibility regulates chemotherapy-induced dormancy and reactivationMol Ther Nucleic Acids20212626927910.1016/j.omtn.2021.07.019Open DOISearch in Google Scholar
Han ML, Zhao YF, Tan CH, Xiong YJ, Wang WJ, Wu F, Fei Y, Wang L, Liang ZQ. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin 2016; 37: 1606–1622. doi: 10.1038/aps.2016.93HanMLZhaoYFTanCHXiongYJWangWJWuFFeiYWangLLiangZQCathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cellsActa Pharmacol Sin2016371606162210.1038/aps.2016.93Open DOISearch in Google Scholar